Recent Updates — EVO
Evotec SE reported Group revenue of €465.0 million for the first nine months of 2026, a 13.1% decline from the prior year period, driven by lower sales conversion in its Discovery & Preclinical Development segment and timing impacts at Just – Evotec Biologics. Adjusted Group EBITDA was a loss of €44.3 million, impacted by €91.9 million in reorganization costs associated with the Horizon transformation program. The company reaffirmed its full-year 2026 guidance for revenue between €570 million and €610 million and adjusted EBITDA between -€105 million and -€70 million. Additionally, Evotec announced that Dr. Joanna Holbrook has been appointed Chief Scientific Officer effective November 1, 2026, succeeding Dr. Cord Dohrmann. The company operates in the life sciences sector, providing drug discovery and development services.
Evotec SE announced the appointment of Dr. Joanna Holbrook as its new Chief Scientific Officer and a Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings over 25 years of experience in pharma, biotechnology, and academia, most recently serving as Therapy Area Head for Cardiovascular, Renal and Hepatic Disease at Novo Nordisk. She will lead Evotec’s global scientific strategy and drive differentiation across its discovery and development services. The filing also includes a notification from the Government of Abu Dhabi regarding major holdings in the company.
Evotec announced preliminary unaudited financial results for the first nine months of 2026. The company expects Group revenues of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures exceed current market expectations, primarily due to the phasing of consensus estimates. Evotec reaffirmed its full-year 2026 guidance, projecting Group revenues between €570 million and €610 million (or €595 million to €635 million at constant exchange rates) and adjusted Group EBITDA between -€70 million and -€105 million (-€60 million to -€90 million at CER). Full financial results for the third quarter and the first nine months will be published on November 5, 2026. Evotec operates in the life sciences sector, providing drug discovery and development services.
Evotec SE announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, following mutual consent between him and the company. Dr. Dohrmann has served as CSO and Member of the Management Board since 2010, playing a significant role in strengthening scientific excellence and establishing key capabilities across platforms including iPSC-based technologies and omics. The search for his replacement is ongoing. Evotec SE operates in the life sciences industry, pioneering drug discovery and development through integrated science, AI-driven innovation, and advanced technologies.
Evotec SE announced the initiation of a Phase 1 clinical trial for JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses. The program was developed by its subsidiary Just – Evotec Biologics under the U.S. Department of War’s Accelerated Antibodies Program in collaboration with BARDA. Manufacturing occurred at the company's J.POD® facility in Redmond using continuous bioprocessing. This contract is part of two agreements with a combined potential value of up to $123.9 million, following an initial 2022 award for plague antibodies. Evotec SE operates as a life science company pioneering drug discovery and development through AI-driven innovation and advanced technologies.
Evotec SE reported first-half 2026 Group revenues of €300.1 million, a 19.2% decline from the prior year period, driven by weak sales conversion and the non-recurrence of a Sandoz license sale in its Just – Evotec Biologics segment. Adjusted Group EBITDA widened to a loss of €42.7 million compared to a €1.9 million loss previously, impacted by €98.9 million in reorganization costs associated with the 'Horizon' transformation and a €42.3 million impairment of a Hamburg laboratory building. The company confirmed an updated full-year 2026 revenue outlook of €570–€610 million and adjusted EBITDA guidance of -€70 to -€105 million, reflecting lower expected contributions from strategic partnerships. Evotec operates in the life sciences industry, providing drug discovery and development services.